Stephens & Co. Reiterates Overweight on Bio-Techne, Maintains $100 Price Target
Portfolio Pulse from richadhand@benzinga.com
Stephens & Co. analyst Jacob Johnson has reiterated an Overweight rating on Bio-Techne (NASDAQ:TECH) and maintained a $100 price target.
August 09, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's stock rating has been reiterated as Overweight by Stephens & Co. with a maintained price target of $100.
The reiteration of an Overweight rating by Stephens & Co. indicates a positive outlook for Bio-Techne. The maintained price target of $100 also suggests that the analyst believes the stock is undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100